FBR Affirms CytRx (CYTR) at 'Outperform' Following Strong Aldoxorubicin Phase 1b/2 Data

October 10, 2016 12:22 PM EDT
Get Alerts CYTR Hot Sheet
Price: $0.45 --0%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 41
Trade CYTR Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

FBR & Co. affirms CytRx Corporation (Nasdaq: CYTR) at Outperform with a price target of $3 after the company presented results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas.

Analyst Christopher James commented today, Today's data demonstrated that more than one-third of evaluable patients achieved a partial response for the target lesion and 61% had prolonged stable disease. While there were nine treatment-associated serious adverse events (SEAs), we point out that no cardiotoxic signals were observed. We believe the final results could represent a positive catalyst for the stock, and reiterate our Outperform rating.

Phase Ib/II study evaluated 36 patients dosed with either 170mg/m2 or 250mg/m2 of aldoxorubicin in combination with ifosfamide/mesna. Interim data demonstrated partial response of the target lesion in 36% of patients, and stable disease in 61% of patients. Six patients, who previously did not qualify for resection were able to achieve over 50% tumor shrinkage over the course of the study, and only one patient showed progressive disease. There were nine SEAs and no treatment-related deaths reported for the study. Importantly, no significant cardiac or dose-limiting toxicities were observed. The company announced that the study will enroll additional patients in the 250mg/m2 dose group.

For an analyst ratings summary and ratings history on CytRx Corp click here. For more ratings news on CytRx Corp click here.

Shares of CytRx Corp closed at $0.54 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment